
The influenza vaccines market overview comprises influenza vaccines marketed for both seasonal and pandemic influenza. Influenza vaccines effectively provide immunity against various influenza strains by activating the immune system to produce specific antibodies. It helps prevent the flu or makes symptoms milder if contracted.
The influenza vaccines market is estimated to be valued at USD 8.30 Bn in 2024 and is expected to reach USD 13.43 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 7.1% from 2024 to 2031.
Key Takeaways
Key players operating in the influenza vaccines market are Integra LifeSciences Corporation, AbbVie Inc., Johnson & Johnson, HansBioMed, Becton, Dickinson and Company, Cook Group, Smith & Nephew Plc., Reprise Biomedical, Organogenesis Holdings Inc., Tissue Regenix, LifeNet Health, Zimmer Biomet Holdings, Inc., Stryker Corporation, MiMedx Group, PolyNovo Limited, Fidia Pharma USA Inc., Baxter International Inc., In2Bones Global, BioHorizons, Inc., Harbor MedTech, Inc., MLM Biologics Inc., Geistlich Pharma AG, Olaregen Therapeutix, Inc., EnColl Corporation, Kerecis limited, DSM, ACell Inc., 3M, Cell Constructs I, LLC, CG bio Inc., and Marine Polymer Technologies, Inc.
The key opportunities in the influenza vaccines market include new product developments targeting specific age groups and strains, potential pandemic opportunities, increasing government support to promote vaccination programs, and growing healthcare Infrastructure across emerging economies.
Globally, manufacturers are focused on expanding their production facilities and distribution networks across Asia Pacific, Latin America, Middle East, and Africa to tap the high growth opportunities in these regions.
Market Drivers
The high prevalence of influenza globally is the major driver for the Influenza Vaccines Market Demand As per WHO, influenza causes severe illness in about 3-5 million cases annually. The availability of government funding for vaccination programs especially in developed countries promotes market growth. Furthermore, growing awareness regarding influenza vaccination benefits and initiatives to promote immunization rates support the influenza vaccines market expansion.
PEST Analysis
Political: Government Influenza Vaccines Market Size And Trends intervention and international funding on vaccine development through programs and regulations. Focus on preventive healthcare.
Economic: Boost in healthcare expenditure. Opportunity for companies to invest in R&D. Vaccine demand expected to rise with awareness.
Social: Growing public health concern regarding influenza outbreaks. Higher vaccine uptake due to health consciousness.
Technological: Advancements in vaccine production technologies. Continuous innovations to address virus mutations.
The United States represents the largest geographical market for influenza vaccines in terms of value, accounting for over 40% share in 2024. Factors such as high healthcare spending, large patient population and rising awareness levels contribute to its leading position.
Asia Pacific region is expected to emerge as the fastest growing regional market for influenza vaccines between 2024-2031. Growing middle class population, increasing government support for vaccination programs and expansion of healthcare infrastructure are driving market growth in countries like China and India. Rising cases of influenza outbreaks also emphasize the need for preventive measures through vaccination in the Asia Pacific region.
Get More Insights On, Influenza Vaccines Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)